申请人:Bristol-Myers Squibb Company
公开号:US05204373A1
公开(公告)日:1993-04-20
The invention relates to novel farnesylated tetrahydro-naphthalenols, that inhibit HMGR activity which results in a decrease in serum total cholesterol, a decrease in LDL cholesterol levels, and inhibition of LDL oxidation. The farnesylated tetrahydro-naphthalenols of the present invention are thus useful for cholesterol/lipid lowering in cases of hypercholesterolemia, hyperlipidemia, and atherosclerosis.
该发明涉及一种新型的韦尼基化四氢萘酚,它抑制HMGR活性,导致血清总胆固醇降低,LDL胆固醇水平降低,以及抑制LDL氧化。因此,本发明的韦尼基化四氢萘酚在高胆固醇血症、高脂血症和动脉粥样硬化病例中用于降低胆固醇/脂质是有用的。